Name | No. | For Patients with | Purpose |
---|---|---|---|
22-09 ADEPPT | 22-09 | Lung caner patients with KRASG12C-mutant NSCLC, including patients aged ≥18 years with poor performance status[Cohort 1] or Elderly (≥70 years) [Cohort 2] |
The purpose of the trial is to assess the clinical efficacy of adagrasib treatment in patients with KRASG12C-mutant NSCLC, in patients who are elderly (≥70 years) or those with poor performance status (ECOG PS=2). |
DSSG Group: Lung
22-23 NeoCOAST-2
Name | No. | For Patients with | Purpose |
---|---|---|---|
22-23 NeoCOAST-2 | 22-23 | Early-Stage (II to IIIA) Non-small Cell Lung Cancer |
The purpose is to evaluate pathologic complete response in patients treated with Durvalumab with Oleclumab or Monalizumab. Also safety and tolerability of Durvalumab. |
BRAND
Name | No. | For Patients with | Purpose |
---|---|---|---|
BRAND | 23-11 | Non-Small Cell Lung Cancer |
The main purpose of this study is see if EBC(Exhaled Breath Condensate) can be used to check for biomarkers which are associated with a radiologic response to chemoimmunotherapy for patients with advanced NSCLC |
SOURCE – LUNG: Stereotactic Ablative Radiation Therapy Of Ultracentral Lung Tumours
Name | No. | For Patients with | Purpose |
---|---|---|---|
SOURCE – LUNG: Stereotactic Ablative Radiation Therapy Of Ultracentral Lung Tumours | 18-33 | inoperable, early stage, high-risk ultracentrally located lung tumours. |
The purpose of the study is to determine the safety of the radiation therapy treatment regimen in terms of side effects experienced within one year after treatment which are related to the radiation therapy. |